ArticleIJU case reports2026

Recurrent TFE3-Rearranged Renal Cell Carcinoma Responding to Pembrolizumab Plus Lenvatinib After Postoperative Pembrolizumab: A Case Report.

Masashi Fujimoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.